MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Small cell lung cancer (SCLC) genetics remain poorly understood, with known alterations including MYC gene amplifications.
• The role of MYC-associated factor X (MAX) in SCLC pathogenesis is largely unexplored.

Purpose of the Study:

• To investigate novel genetic alterations in SCLC.
• To elucidate the functional relationship between MAX, MYC, and the SWI/SNF complex in SCLC.

Main Methods:

• Analysis of SCLC tumor samples for genetic alterations in MAX.
• Functional studies involving BRG1 depletion in MAX-deficient SCLC cells.
• Investigation of BRG1's role in regulating MAX expression and MYC targets.

Main Results:

• Discovered tumor-specific inactivation of the MAX gene in SCLC.
• MAX inactivation is mutually exclusive with MYC and BRG1 alterations.
• BRG1 directly regulates MAX expression and is essential for cell growth in MAX-deficient cells, indicating a synthetic lethal interaction.
• BRG1 is required for MAX to activate neuroendocrine programs and upregulate MYC targets like glycolysis genes.
• Inactivation of MGA, a MAX dimerization partner, was observed in both SCLC and non-small cell lung cancer.

Conclusions:

• Aberrant SWI/SNF-MYC network interactions are critical for lung cancer development.
• Targeting BRG1 may be a therapeutic strategy for MAX-deficient SCLC.
• MAX inactivation represents a significant finding in SCLC genetics.